Notice of Results and Investor Presentation
Source: RNS
Cambridge Nutritional Sciences plc
(the 'Company' or 'CNS')
Notice of Results and Investor Presentation
Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, confirms it will issue its Half Year results for the six months ended 30 September 2023 on Thursday 23 November 2023.
Investor presentation
Jag Grewal, CEO and Simon Douglas, Chairman will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on Thursday 23 November 2023 at 16:30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Cambridge Nutritional Sciences plc via:
https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor
Investors who already follow Cambridge Nutritional Sciences plc on the Investor Meet Company platform will automatically be invited.
Contacts:
|
Cambridge Nutritional Sciences plc |
||||
|
Jag Grewal, Chief Executive Officer |
via Walbrook PR |
|||
|
|
|
|||
|
|
|
|||
|
Cavendish Capital Markets Limited |
Tel: 020 7220 0500 |
|||
|
Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance) |
|
|||
|
Nigel Birks / Harriet Ward (ECM) |
|
|||
|
|
|
|||
|
|
|
|||
|
Walbrook PR Limited |
Tel: 020 7933 8780 or CNS@walbrookpr.com |
|||
|
Paul McManus / Sam Allen |
Mob: 07980 541 893 / 07502 558 258 |
|||
|
|
|
|||
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
